Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections

扎那米韦微针治疗流感感染

• 批准号: 10614045
• 负责人: Elke Lipka
• 金额: $ 99.96万
• 依托单位: TSRL, INC.
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10614045
• 关键词: Acute; Adamantane; Address; Agreement; COVID-19 pandemic; Cessation of life; Characteristics; Circulation; Clinical; Communities; Data; Development; Development Plans; Devices; Disease; Dose; Drug Kinetics; Dryness; Effectiveness; Elderly; Engineering; Ensure; Epidemic; Epithelium; Family suidae; Formulation; Future; Human; Hydrogels; Influenza; Influenza prevention; Inhalation; Inhalation Drug Administration; Kinetics; Light; Liquid substance; Literature; Lung; Marketing; Medical; Methods; Miniature Swine; Modeling; Needles; Neuraminidase inhibitor; Oral; Oseltamivir; Pain; Painless; Pathogenicity; Patients; Persons; Pharmaceutical Preparations; Pharmaceutical Services; Pharmacotherapy; Phase; Population; Powder dose form; Property; Publishing; Puncture procedure; Rattus; Recommendation; Research; Resistance; Respiratory System; Risk; Route; Safety; Seasons; Site; Skin; Small Business Innovation Research Grant; Specific qualifier value; Syringes; System; Therapeutic; Toxicology; Transdermal substance administration; Vaccination; Vaccines; Visit; Work; absorption; clinical development; economic impact; effective therapy; endonuclease; flu; improved; influenza epidemic; influenza infection; influenza outbreak; influenza virus strain; influenzavirus; inhibitor; manufacturability; manufacture; mortality; novel; novel therapeutics; pandemic disease; patient population; pharmacokinetics and pharmacodynamics; pre-Investigational New Drug meeting; preclinical study; prevent; product development; programs; prototype; resistant strain; respiratory; scale up; seasonal influenza; skin barrier; transmission process; vaccine effectiveness; zanamivir

Abstract Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is <0.03%, but with significant mortality in the young and the elderly populations. When a new pathogenic influenza strain enters the population, a pandemic could kill tens of millions of people with a negative economic impact estimated to be over 150 billion dollars. Due to the incomplete efficacy of the current vaccines, effective drug treatment is necessary. Presently, influenza treatment is only somewhat effective, and some influenza strains are resistant to the currently marketed therapeutics, adamantanes and the neuraminidase inhibitor Tamiflu®. However, while zanamivir (ZAN, Relenza®) remains highly active against oseltamivir-resistant influenza strains, its therapeutic impact is severely limited by its route of administration, via oral inhalation, which renders it unsuitable for patients with a compromised respiratory system. Therefore, development of a novel delivery alternative for ZAN as we propose here, is poised to address a significant unmet medical need. Transdermal drug delivery offers a number of improvements over other delivery systems. The drug directly enters the systemic circulation, circumventing absorption and first-pass barriers typical for oral delivery. It avoids skin puncture by syringe needles, eliminating pain and patient visits to a clinician. Transdermal delivery of ZAN could allow large numbers of patients to be reached during an influenza outbreak, which will be particularly important in light of the added risk during the ongoing COVID-19 pandemic. While ZAN itself cannot cross the human skin barrier at therapeutic rates, Microneedle (MN) - enhanced transdermal delivery is an elegant, efficient, and painless method for increasing the skin permeation of many drugs, including ZAN. Our novel drug-device combination product, TSR-066, consists of a swellable MN patch, which will continuously deliver ZAN over 5 days. This CRP proposal will support optimization and scale-up of the ZAN MN formulation and subsequent IND- enabling toxicology studies in minipigs. We have obtained agreement with the FDA on the preclinical studies needed in order to open the IND, as well as on the Phase I clinical development plans and the 505(b)2 regulatory strategy. In addition to the experimental work proposed here, we will develop a robust IP expansion strategy for the current ZAN MN product, as well as future product candidates that stand to benefit from MN-enabled delivery. The end result of this work will be a novel, transdermal delivery approach for ZAN, which will expand its reach into patient groups for which Relenza® is contraindicated and allow for simple administration for ZAN for both treatment and prevention of the flu. We have assembled a team of expert advisors and collaborators to ensure successful completion of this research plan.

抽象的 每年流感流行都会袭击数百万人，造成多达 50 万人死亡。 季节性流感病毒<0.03%，但在年轻人和老年人群中死亡率很高。 当一种新的致病性流感毒株进入人群时，大流行可能会导致数千万人死亡 由于效果不完全，预计造成的负面经济影响超过 1500 亿美元。 目前，有效的疫苗、药物治疗是必要的。目前，流感的治疗只是有所作为。 有效，并且某些流感毒株对目前市售的治疗药物金刚烷类和 神经氨酸酶抑制剂达菲® 然而，扎那米韦（ZAN、Relenza®）仍然具有高度活性。 奥司他韦耐药流感病毒株，其治疗效果受到其给药途径的严重限制， 口服吸入，这使得它不适合呼吸系统受损的患者。 正如我们在此提出的，为 ZAN 开发一种新颖的交付替代方案，有望解决一个重大的未满足问题 医疗需要。 与其他递送系统相比，透皮药物递送提供了许多改进，药物直接进入。 全身循环，避免口服给药典型的吸收和首过障碍。 通过注射器针头穿刺，可以消除疼痛并减少患者就诊 ZAN 的情况。 在流感爆发期间能够接触到大量患者，这一点尤为重要 鉴于当前的 COVID-19 大流行期间增加了风险，而 ZAN 本身无法穿过人体皮肤。 微针 (MN) - 增强的透皮递送是一种优雅、高效且可靠的治疗速率屏障 增加许多药物（包括 ZAN）皮肤渗透的无痛方法。 组合产品 TSR-066 由可膨胀的 MN 贴片组成，可连续提供超过 5 个 ZAN 该 CRP 提案将支持 ZAN MN 配方的优化和扩大以及后续的 IND- 我们已与 FDA 就临床前研究达成一致。 启动 IND 以及 I 期临床开发计划和 505(b)2 监管所需的 除了这里提出的实验性工作之外，我们还将制定一个强大的知识产权扩展策略。 当前的 ZAN MN 产品，以及将从支持 MN 的交付中受益的未来候选产品。 这项工作的最终结果将是为 ZAN 提供一种新颖的透皮给药方法，这将扩大其覆盖范围 分为 Relenza® 禁忌的患者组，并允许简单地给予 ZAN 我们组建了一个由专家顾问和合作者组成的团队，以确保流感的治疗和预防。 顺利完成本研究计划。